SCHEMBL3724926

SCHEMBL3724926

O=C(O)[C@@H](Cc1ccccc1)N(Cl)Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.55
ALPI P09923 1/20 0.52
PKM P14618 1/20 0.52
PTGS1 P23219 1/20 0.52
XIAP P98170 1/20 0.52
SLC7A5 Q01650 1/20 0.52
CPA3 P15088 3/20 0.48
CPA1 P15085 2/20 0.48
FOLH1 Q04609 1/20 0.48
CPB1 P15086 1/20 0.48
CPB2 Q96IY4 1/20 0.48
ADAMTS5 Q9UNA0 2/20 0.48
SRR Q9GZT4 2/20 0.47
SLC1A3 P43003 2/20 0.47
SLC1A2 P43004 2/20 0.47
SLC1A1 P43005 2/20 0.47
NPSR1 Q6W5P4 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MDM2 Q00987 1/20 0.46
ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1573822 1.00 CYP1A2 (0.55) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL296747 1.00 CYP1A2 (0.55) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL2238484 0.88 MME (0.48) CYP1A2CPA1FOLH1NPSR1
SCHEMBL2238482 0.88 MME (0.48) CYP1A2CPA1FOLH1NPSR1
SCHEMBL607090 0.85 SLC7A5 (0.55) SLC7A5FOLH1
SCHEMBL607091 0.85 SLC7A5 (0.55) SLC7A5FOLH1
SCHEMBL11710892 0.82 ADAMTS5 (0.50) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL31114841 0.82 ADAMTS5 (0.50) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL2466759 0.82 CYP1A2 (0.57) CYP1A2ALPIPKMPTGS1XIAP
SCHEMBL157789 0.82 CYP1A2 (0.57) CYP1A2ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9993516-B2 Treatment of left ventricular non-compaction and dilated cardiomyopathy by inhibiting melanocortin receptor four THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2018-06-12 US claimed
US-20160296587-A1 THERAPIES FOR LEFT VENTRICULAR NON-COMPACTION AND DILATED CARDIOMYOPATHY THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2016-10-13 US claimed
WO-2015077334-A2 THERAPIES FOR LEFT VENTRICULAR NON-COMPACTION AND DILATED CARDIOMYOPATHY THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2015-05-28 WO claimed
EP-0063423-B1 GNRH ANTAGONISTS THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1985-08-14 EP claimed
EP-0038135-B1 LRF ANTAGONISTS THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1984-07-11 EP claimed
US-4409208-A PEPTIDES WHICH INHIBIT GONADOTROPINS THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1983-10-11 US claimed
US-4386074-A DECAPEPTIDE ANALOGS OF LUTEINIZING HORMONE-RELEASING HORMONE THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1983-05-31 US claimed
EP-0063423-A1 GnRH antagonists THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1982-10-27 EP claimed
EP-0047079-A1 Nonapeptides affecting gonadal function THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1982-03-10 EP claimed
EP-0038135-A2 LRF antagonists THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1981-10-21 EP claimed
US-9993516-B2 Treatment of left ventricular non-compaction and dilated cardiomyopathy by inhibiting melanocortin receptor four THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2018-06-12 US disclosed
EP-3125906-A1 PEPTIDE FRAGMENTS OF NETRIN-1 AND COMPOSITIONS AND METHODS THEREOF The Regents of the University of California (US) 2017-02-08 EP disclosed
US-20160296587-A1 THERAPIES FOR LEFT VENTRICULAR NON-COMPACTION AND DILATED CARDIOMYOPATHY THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2016-10-13 US disclosed
WO-2015153402-A1 PEPTIDE FRAGMENTS OF NETRIN-1 AND COMPOSITIONS AND METHODS THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-10-08 WO disclosed
WO-2015077334-A2 THERAPIES FOR LEFT VENTRICULAR NON-COMPACTION AND DILATED CARDIOMYOPATHY THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2015-05-28 WO disclosed
EP-0063423-A1 GnRH antagonists THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1982-10-27 EP disclosed
EP-0047079-A1 Nonapeptides affecting gonadal function THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1982-03-10 EP disclosed
EP-0047079-A1 Nonapeptides affecting gonadal function THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1982-03-10 EP disclosed
EP-0038135-A2 LRF antagonists THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1981-10-21 EP disclosed
EP-0038135-A2 LRF antagonists THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1981-10-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160296587-A1 THERAPIES FOR LEFT VENTRICULAR NON-COMPACTION AND DILATED CARDIOMYOPATHY TNNI3, TNNT2, TNNC1 CYP1A2 4865/4885ALPI 4612/4885PKM 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.